share_log

Merck's Keytruda Shows Better Disease-Free Survival As Adjuvant Therapy In Kidney Cancer

Merck's Keytruda Shows Better Disease-Free Survival As Adjuvant Therapy In Kidney Cancer

默克公司的Keytruda作為腎癌的輔助治療顯示更好的無病生存率
Benzinga Real-time News ·  2021/04/08 20:26
  • Merck & Co Inc (NYSE: MRK) has announced interim data from Phase 3 KEYNOTE-564 trial evaluating Keytruda as a potential adjuvant treatment of renal cell carcinoma (RCC) following nephrectomy (surgical removal of a kidney) or following nephrectomy and resection of metastatic lesions.
  • Based on an interim analysis conducted by an independent Data Monitoring Committee, Keytruda monotherapy demonstrated a statistically significant and clinically meaningful improvement in DFS compared with placebo.
  • The trial will continue to evaluate overall survival (OS), a key secondary endpoint. The safety profile of KEYTRUDA in this trial was consistent with that observed in previously reported studies.
  • Merck will present the results at an upcoming medical meeting and submit them to regulatory authorities.
  • Keytruda is currently approved in the U.S., Europe, and Japan combined with axitinib for the first-line treatment of patients with advanced RCC.
  • Price Action: MRK shares are up 0.37% at $76.4 in premarket trading on the last check Thursday.
  • 默克公司(Merck&Co Inc.)亞洲網加利福尼亞州聖何塞2月18日電(紐約證券交易所市場代碼：MRK)公佈了第3階段Keytrnote-564試驗的中期數據，該試驗評估Keytruda作為腎切除(腎臟手術切除)或腎切除和轉移病灶切除後的腎細胞癌(RCC)的潛在輔助治療。
  • 根據一個獨立的數據監測委員會進行的中期分析，Keytruda單一療法與安慰劑相比，在DFS方面顯示出統計上顯著的和臨牀上有意義的改善。
  • 該試驗將繼續評估總存活率(OS)，這是一個關鍵的次要終點。KEYTRUDA在本試驗中的安全性情況與先前報道的研究中觀察到的情況一致。
  • 默克公司將在即將召開的醫療會議上公佈結果，並提交給監管機構。
  • Keytruda目前在美國、歐洲和日本被批准與Axitinib聯合用於晚期腎癌患者的一線治療。
  • 價格行動：在週四最後一張支票的盤前交易中，Mr k股價上漲0.37%，至76.4美元。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論